drugset / Trial / NCT00272766
Macugen for Histoplasmosis
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effect on visual acuity of Macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS).
Timeline
- Start
- 2006-02
- Primary completion
- —
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pegaptanib sodium | Aptamer | 0.3 mg | Intravitreal |